Enrollment in Eli Lilly’s advanced trial of her monoclonal antibody treatment is on hold due to potential safety concerns following a recommendation from U.S. health regulators.
Continue reading below
JOHNSON & JOHNSON REPORTS STRONG THIRD QUARTER BENEFITS AFTER BREAK IN CORONAVIRUS VACCINE STUDY
“Safety is of the utmost importance to Lilly,” an Eli Lilly spokesperson told FOX Business on Tuesday. a pause in registration. ”
The trial is used to test the safety and effectiveness of Eli Lilly’s antibody therapy for hospital patients battling COVID-19, and is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), which makes part of the National Institutes of Health (NIH).
A spokesperson for the National Institute of Allergy and Infectious Diseases did not return FOX Business’s request for comment at the time of posting.
GET FOX BUSINESS ON THE ROAD BY CLICKING HERE
Eli Lilly submitted an emergency use authorization request to the Food and Drug Administration last week for his treatment with LY-CoV555 antibodies. The company said in a press release that it expects to be able to deliver up to 100,000 doses by the end of October, and up to 1 million by next year.
|LLY||ELI LILLY & COMPANY||150,08||-4,41||-2,85%|
|JNJ||JOHNSON & JOHNSON||148,36||-3,48||-2,29%|
The announcement comes just a day after Johnson and Johnson said they would suspend their coronavirus vaccine research study due to an adverse reaction from one of the participants.
Eli Lilly stock is currently trading around $ 149 per share, down more than 3% in Tuesday’s trading session.
CLICK HERE TO LEARN MORE ABOUT FOX BUSINESS